A Network for Innovation: Excellos’ Partnership with Blood Centers of America

A Network for Innovation: Excellos’ Partnership with Blood Centers of America Strong partnerships are essential to delivering consistent, high-quality starting material for cell and gene therapy—and our collaboration with Blood Centers of America (BCA), through San Diego Blood Bank, is a great example of that impact in action. Our Blood Centers of America Partnership Journey […]
The Excell-ence Exclusive: Advancing Cell Therapy Innovations | May 2025

Welcome back to The Excell-ence Exclusive! Your quarterly source for expert insights into cell therapy manufacturing. In each issue, we share thought-provoking articles from the Excellos scientific team, highlighting technical expertise, industry trends, and best practices to help you accelerate your projects and stay ahead in the fast-moving world of cell therapy. Contact us for […]
Starting Strong: Why Your Cell Therapy Begins with the Right Material

When it comes to cell therapy, your starting material can make all the difference — not just in outcomes, but in efficiency, reproducibility, and long-term success. At Excellos, we believe the quality and consistency of your donor material should never be an afterthought. Through our deep partnership with San Diego Blood Bank, we offer more […]
Proud to Be Part of ARM: Advancing the Future of Regenerative Medicine Together

Proud to Be Part of ARM: Advancing the Future of Regenerative Medicine Together At Excellos, we are honored to be a member of the Alliance for Regenerative Medicine—a driving force behind the progress, innovation, and advocacy that is transforming the field of regenerative medicine. Alliance for Regenerative Medicine also known as ARM As a member […]
Spotlight on Excell-ence: Quality Assurance Team

Spotlight on Excellence: Cell Therapy Quality Assurance Team The value of a QA team at a cell therapy CDMO lies in their ability to ensure that every aspect of the development and manufacturing process is performed with the highest level of quality, safety, and regulatory compliance. Their role ensures that the products manufactured are safe, […]
Excellos Launches Cell Therapy Manufacturing Newsletter: Innovation Updates in CAR-T and GMP Production

Find how you can see state-of-the-art manufacturing, why decentralized manufacturing makes sense, and why mito functions are key to selecting CAR-T donors. Excellos Newsletter Launches Focusing on Innovations in Cell Therapy Manufacturing Find how you can see state-of-the-art manufacturing, why decentralized manufacturing makes sense, and why mito functions are key to selecting CAR-T donors. Welcome […]
Spotlight on Excell-ence: Project Management Team

Excellos project management team At Excellos, our success is built on the expertise and dedication of our incredible teams. In this ongoing series, we’re highlighting the people behind the innovation—showcasing the teams that make our work possible. First up, our Project Management Team: the experts ensuring seamless execution and unparalleled customer support. Meet Erin Darnley, […]
Excellos & SDBB: A Legacy of Innovation and Impact

Excellos: From Blood Bank Division to Leading Cell Therapy CDMO | A Legacy of Innovation At Excellos, we are driven by a mission that seamlessly blends cutting-edge science with a legacy of service. Our journey began as a division of the San Diego Blood Bank (SDBB), a nonprofit with over 70 years of experience in […]
Excellos Ensures Reliability and Patient Safety with XiltriX

This case study is available as a downloadable PDF for offline reading.
Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos’ CAR-T Cell Therapy

Excellos Selected as Decentralized Manufacturing Unit to Support Galapagos’ CAR-T Cell Therapy Clinical Study Close to Cancer Treatment Centers in the San Diego Area Excellos is the first decentralized manufacturing unit (DMU) within the nationwide network of Blood Centers of America to be selected for Good Manufacturing Compliant (GMP) manufacturing for Galapagos’ CAR-T hemato-oncology […]